CAR-T Meeting 2024 | The evidence needs in CAR-T from the patient perspective: capturing the patient experience
Lorna Warwick
• 17 Feb 2024
Lorna Warwick, BSc, Lymphoma Coalition, Toronto, Canada, comments on the evidence needs of patients receiving CAR T-cell therapy. As CAR-T is a novel therapeutic option, insufficient tools exist for monitoring and understanding the effects of the treatment on patients’ quality of life (QoL). Several projects are underway to develop and validate questionnaires and tools that will allow the patient experience to be appropriately captured. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
